Participated · Equity · Dec 2020

BrainsGate announced a $14 million funding round on December 7, 2020. The round was led by new investors Spero Ventures and BNP Joint Capital Fund, a fund managed by BNPP Capital Partners. Returning investors included Elron Electronic Industries Ltd., Agate Medical Investments, Medtronic plc, Pitango Venture Capital, and Cipio Partners. The transaction was raised at a pre-money valuation of $147 million. The article does not disclose the company’s product details, future plans, or operating metrics.

Participated · Series C · Apr 2019

Rapid Medical develops responsive, adjustable neurovascular devices for endovascular diseases, with a focus on minimally invasive treatment of ischemic and hemorrhagic stroke. The company’s flagship TIGERTRIEVER revascularization device received FDA clearance for treatment of ischemic stroke. TIGERTRIEVER 13 is CE marked and is the smallest device in the portfolio, indicated for removal of clots from more distal areas of the brain; TIGERTRIEVER 13 is not FDA cleared. TIGERTRIEVER 17 and 21, COMANECI and COLUMBUS/DRIVEWIRE are CE marked and FDA cleared. Rapid Medical uses a proprietary braiding technology platform and plans to expand commercial operations in the US and Europe, generate additional clinical evidence, advance its product pipeline, and pursue regulatory approvals in strategic territories such as China. Rapid Medical develops interventional neurovascular devices for endovascular treatments and is led by CEO and co-founder Ronen Eckhouse. The company makes TIGERTRIEVER, a controllable, fully visible stentriever for ischemic stroke, and COMANECI, a controllable aneurysm neck-bridging device. Both TIGERTRIEVER and COMANECI are CE marked for use in Europe. Rapid Medical intends to use the Series C proceeds to develop a U.S. commercial presence ahead of regulatory approvals, expand sales and marketing in Europe, and develop additional products. It will also support completion of the TIGER IDE study in the U.S., which has been enrolling patients since May 2018. The company has entered a partnership granting MicroPort marketing rights for TIGERTRIEVER and COMANECI in China. Rapid Medical, led by Dr. Shimon Eckhouse, develops neurovascular interventional devices including TIGERTRIEVER and COMANECI. TIGERTRIEVER is a visible and controllable stentriever designed to treat ischemic stroke, while COMANECI is an aneurysm collar bridging device. Both devices are CE marked and have been used in neurovascular procedures for thousands of patients in Europe. The company closed a $9M Series B financing round to support regulatory and commercial efforts. Rapid Medical intends to use the funds to facilitate U.S. regulatory approvals and to pursue marketing of the two devices in the European market. As part of the financing, investor representatives will join the company's board.

Participated · Seed · Mar 2016

DiA Imaging Analysis, based in Beer Sheva, Israel, provides FDA-cleared and CE-marked AI-based ultrasound solutions that help clinicians capture the right images and automatically identify clinical abnormalities. Its vendor-neutral, cross-platform LVivo Toolbox is deployed on ultrasound devices and healthcare IT systems and currently serves thousands of end-users in more than 20 countries. The company announced an additional $14M in funding and plans to use the proceeds to expand its portfolio of solutions and grow its global presence in Asia, Europe and the U.S. It intends to pursue new and expanded partnerships with ultrasound vendors, PACS/Healthcare IT companies, resellers, and distributors. DiA has established channel and commercial partnerships with major healthcare technology providers and distributors including IBM Watson, Philips, GE Healthcare, and Konica Minolta. The company also added Dr. Diku Mandavia to its Board of Directors as an industry board member. DiA Imaging Analysis develops FDA- and CE-cleared cognitive image-processing software that provides fully automated ultrasound analysis, with its first product line focused on echocardiography. Its tools use advanced pattern recognition and machine-learning algorithms to automatically detect borders and motion and produce quantitative data for clinicians. The company integrates its software within ultrasound devices, healthcare IT systems and cloud platforms through partnerships with vendors including GE Healthcare, Neusoft Medical System and Google Cloud. DiA has reference sites at leading U.S. medical centers including Yale, Mount Sinai, RUSH, USF and UCSD, and its scientific advisory board is supported by cardiology and primary care ultrasound specialists. Founded by Hila Goldman Aslan (CEO), Michal Yaacobi (VP R&D) and Arnon Toussia-Cohen (VP BD), the Be'er Sheva–based company plans to expand its portfolio and build support teams in the United States, Europe and Asia. DiA closed a $5M funding round to support market penetration of its automated tools and further product development. DiACardio, founded in 2010 and based in Beer Sheva’s Hi-Tech Park, develops FDA- and CE-approved software that automatically evaluates heart function from ultrasound images. The company leverages new image-processing methods and proprietary algorithms to provide automated cardiac evaluation. DiACardio has 10 employees and has already obtained initial sales. It raised $1.95M in a post-seed financing to support growth. The company plans to use the funds to expand its automated toolbox to other areas of the heart and to grow its business in the US, Europe and emerging markets. The founding team includes Arnon Toussia-Cohen, Hila Goldman-Aslan, Michal Yaacobi, Dr. Noah Liel-Cohen and Prof. Hugo Guterman.

Participated · Series C · Jul 2015

MST develops image‑guided surgical systems built on a proprietary image analytic technology platform; its flagship product is AutoLap®, an FDA‑cleared and CE‑approved image‑guided laparoscope positioning system. AutoLap® offers surgeons hands‑free, natural control of laparoscopic procedures with minimal user interaction and is aimed at the large minimally invasive surgery market. The company says healthcare providers benefit from cost‑effective technology that can enable more efficient procedures. MST is privately held, was founded in 2005, and is based in Yokneam, Israel. Management plans to use the recent investment primarily to expand marketing and sales of AutoLap® in the U.S., Europe and China. As part of the deal, the lead investor Haisco will serve as AutoLap®’s exclusive distributor in China.

Participated · Equity · Feb 2014

Ornim is a commercial-stage medical-technology company based in Kfar Saba, Israel, that focuses on clinical research, development and distribution of devices for tissue and cerebral blood flow and perfusion. Its FDA-cleared lead product, the c-FLOW™, is a non-invasive bedside monitor that provides real-time blood flow and perfusion measurements to the brain and other vital tissues. The c-FLOW™ is based on Ornim’s proprietary UTLight™ technology, which combines near-infrared light with ultrasound pulses, and has been clinically validated to measure cerebral and muscle tissue blood-flow changes. The company is led by president and CEO Israel Schreiber. Ornim intends to use new funds to accelerate U.S. commercial expansion and to obtain China Food and Drug Administration clearance for the c-FLOW™, with commercialization in China targeted for the second half of 2017 upon clearance. Ornim Medical develops non-invasive patient monitoring solutions for cerebral and tissue blood flow based on its patented UTLight™ technology. Its primary products are the CerOx™ and c-FLOW™ devices, intended for use in operating rooms, neuro-critical care and intensive care units, recovery rooms, and emergency rooms. The company says it plans future use in ambulances and MediVac. Ornim employs about 30 professionals including doctors, physicists, bio-engineers and researchers. Led by CEO Israel Schreiber, the company is advancing product development and international marketing efforts. The article reports a completed funding round to support those goals. Ornim develops the CerOx™ monitor, an FDA-cleared and CE-marked device that uses near-infrared spectroscopy combined with ultrasound to continuously and non-invasively measure regional hemoglobin oxygen saturation and microcirculation blood flow in tandem. The CerOx is designed for adult patients and intended for use across clinical settings including the operating room and intensive care unit. Ornim expects the combined measurement of oxygen saturation and blood flow to be essential during procedures under general anesthesia, for monitoring brain-injured patients, and during resuscitation. The company plans to launch the CerOx monitor in the U.S. and European markets within the next 18 months. Proceeds from the recent financing will fund further product development, clinical studies, and international marketing and commercialization.